 WARREN, N.J., Oct. 06, 2021 GLOBE NEWSWIRE -- Aquestive Therapeutics, Inc. NASDAQ: AQST, a pharmaceutical company focused on developing and commercializing differentiated products that address patients unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders providing for a bridge waiver of the first principal payment due under its 12.5 Senior Secured Notes the Notes in order to provide sufficient time for the parties to execute a definitive agreement to extend the time when the first principal payment is due under the Notes to March 30, 2023. 